Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Salix paying $60M up front for Progenics' constipation drug, but investor relief short-lived

This article was originally published in Scrip

Executive Summary

The news that Progenics Pharmaceuticals found a new partner for its opioid-induced constipation medicine Relistor (methylnaltrexone bromide) in fellow bowel drug maker Salix Pharmaceuticals, which licensed the exclusive worldwide rights for the product, except for Japan, in exchange for $60 million upfront and potentially $290 in milestones, had investors relieved 7 February, although the stimulation of the deal tapered off as the day wore on, with both firms' shares down at the bell.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC011798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel